A dissolved conglomerate stronger than ever before
There was a time in American history when the name General Electric meant everything — light bulbs, trains, finance, jet engines, and a bit of everything in between. Founded by a few of the most notable men of the 19th and 20th centuries, including Thomas Edison and J.P. Morgan, for decades the company stood for American innovation and success. Then came two decades of chaos, overexpansion, and near self-destruction. The GE of today, though, looks nothing like that bloated behemoth. It’s leaner, clearer, and, frankly, one of the most exciting industrial transformations of our time. This post has nothing to do with my portfolio, but GE’s transformation is one of the most exciting stories in U.S. business history.
Last year, GE finally completed an inevitable split into three world-class businesses, each strong enough to stand on its own: GE Aerospace, GE Vernova, and GE Healthcare — three independent pillars that together are worth north of half a trillion dollars in market cap. What was once the symbol of American corporate confusion has turned into a showcase of strategic clarity.
Let’s start with the crown jewel and investors’ favorite: GE Aerospace. With a market cap around $315 billion, it’s not just GE’s largest child, it’s the engine room of modern aviation. Literally. It powers most of the world’s commercial fleets through partnerships with Boeing and Airbus and maintains a near-duopoly with Rolls-Royce and Pratt & Whitney. Demand is surging as airlines rebuild capacity post-COVID, and engine replacement cycles stretch for decades. Airbus and Boeing have order books filled for decades, and GE Aerospace profits from every single one of them. But contrary to the two manufacturing behemoths, GE is largely recession-proof. Even if orders slow, GE’s services will always be needed. It’s a compounding machine equipped with long-term contracts, recurring service revenue, and a backlog so large it would make Rheinmetall jealous. Aerospace is not just growing — it’s booming.
Then comes GE Vernova, the newest and arguably most innovative piece. With a valuation around $155 billion, it’s GE’s bet on the energy transition. Vernova covers everything from gas turbines to renewables and grid infrastructure. What makes it fascinating is the dual exposure: it earns cash from legacy energy while scaling renewables at record speed. The world’s massive push toward decarbonization is turning Vernova into an unprecedented industrial growth story. Its mix of predictable cash flow and clean-energy momentum is the kind of combination that gives long-term investors goosebumps. Politics don’t affect Vernova, because it plays both sides and can easily shift depending on the region.
And then there’s GE Healthcare, the quiet one. Valued at around $35 billion, it hasn’t had the same explosive trajectory as its siblings. The business remains solid — MRI, CT, and diagnostic equipment are steady earners — but growth has lagged. Margins are thinner, innovation cycles slower, and competition from Siemens Healthineers and Philips remains tough. The spinoff made sense; it gave investors the option to own steady healthcare profits without the industrial noise. But it seems like investors prefer the noise a lot more than quiet healthcare compounders. And who can blame them? In the end, most of us prefer the excitement of an aerospace pioneer over legacy medical technology.
I think what GE did with this three-way split is ingenious. Investors can now choose what they want to own rather than buying into an opaque conglomerate. There are three distinct paths: an aerospace powerhouse, an energy platform, and a steady healthcare operator.
GE was the ultimate cautionary tale — proof that size and diversification can kill greatness, and concentration is what really excites the crowd.
Sometimes, to rebuild a legend, you first have to dismantle it.
